$BMRN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in BIOMARIN PHARMACEUTICAL INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in BIOMARIN PHARMACEUTICAL INC. Get notifications about new insider transactions in BIOMARIN PHARMACEUTICAL INC for free.
Page: < prev 1 ... 2 3 4 5 6 7 8 9 ... 34 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 07 2018 | BMRN | BIOMARIN PHARMACEU ... | MEIER RICHARD A | Director | Grant | A | 0.00 | 4,300 | 0 | 56,610 | 52.3 K to 56.6 K (+8.22 %) |
| Jun 07 2018 | BMRN | BIOMARIN PHARMACEU ... | LEWIS ALAN | Director | Grant | A | 0.00 | 4,300 | 0 | 25,360 | 21.1 K to 25.4 K (+20.42 %) |
| Jun 06 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 92.07 | 1,711 | 157,532 | 61,070 | 62.8 K to 61.1 K (-2.73 %) |
| Jun 06 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 68.78 | 167 | 11,487 | 62,781 | 62.6 K to 62.8 K (+0.27 %) |
| Jun 06 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Payment of Exercise | F | 92.07 | 346 | 31,856 | 15,050 | 15.4 K to 15.1 K (-2.25 %) |
| Jun 06 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 92.07 | 1,414 | 130,187 | 51,571 | 53 K to 51.6 K (-2.67 %) |
| Jun 06 2018 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Payment of Exercise | F | 92.07 | 1,562 | 143,813 | 83,276 | 84.8 K to 83.3 K (-1.84 %) |
| Jun 06 2018 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Grant | A | 68.78 | 309 | 21,254 | 84,838 | 84.5 K to 84.8 K (+0.37 %) |
| Jun 06 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Payment of Exercise | F | 92.07 | 6,310 | 580,962 | 284,290 | 290.6 K to 284.3 K (-2.17 %) |
| Jun 06 2018 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Payment of Exercise | F | 92.07 | 1,934 | 178,063 | 155,167 | 157.1 K to 155.2 K (-1.23 %) |
| Jun 06 2018 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Grant | A | 68.78 | 309 | 21,254 | 157,101 | 156.8 K to 157.1 K (+0.20 %) |
| Jun 06 2018 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Payment of Exercise | F | 92.07 | 1,414 | 130,187 | 86,950 | 88.4 K to 87 K (-1.60 %) |
| Jun 06 2018 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Grant | A | 68.78 | 309 | 21,254 | 88,364 | 88.1 K to 88.4 K (+0.35 %) |
| May 18 2018 | BMRN | BIOMARIN PHARMACEU ... | MEIER RICHARD A | Director | Option Exercise | M | 38.59 | 15,000 | 578,850 | 0 | |
| May 18 2018 | BMRN | BIOMARIN PHARMACEU ... | MEIER RICHARD A | Director | Buy | M | 38.59 | 15,000 | 578,850 | 51,310 | 36.3 K to 51.3 K (+41.31 %) |
| May 18 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 38.59 | 18,750 | 723,563 | 0 | |
| May 18 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 88.66 | 18,750 | 1,662,356 | 290,600 | 309.4 K to 290.6 K (-6.06 %) |
| May 18 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 38.59 | 18,750 | 723,563 | 309,350 | 290.6 K to 309.4 K (+6.45 %) |
| May 17 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 38.59 | 18,750 | 723,563 | 18,750 | |
| May 17 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 89.13 | 18,750 | 1,671,131 | 290,600 | 309.4 K to 290.6 K (-6.06 %) |
| May 17 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 38.59 | 18,750 | 723,563 | 309,350 | 290.6 K to 309.4 K (+6.45 %) |
| May 16 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 38.59 | 18,750 | 723,563 | 37,500 | |
| May 16 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 38.59 | 18,750 | 723,563 | 56,250 | |
| May 16 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 88.29 | 18,750 | 1,655,434 | 290,600 | 309.4 K to 290.6 K (-6.06 %) |
| May 16 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 38.59 | 18,750 | 723,563 | 309,350 | 290.6 K to 309.4 K (+6.45 %) |
| May 16 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 89.22 | 18,750 | 1,672,851 | 290,600 | 309.4 K to 290.6 K (-6.06 %) |
| May 16 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 38.59 | 18,750 | 723,563 | 309,350 | 290.6 K to 309.4 K (+6.45 %) |
| May 14 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Sell | S | 89.50 | 2,450 | 219,275 | 15,396 | 17.8 K to 15.4 K (-13.73 %) |
| May 14 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Grant | A | 68.78 | 287 | 19,740 | 17,846 | 17.6 K to 17.8 K (+1.63 %) |
| May 14 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 38.59 | 18,750 | 723,563 | 75,000 | |
| May 14 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 38.59 | 18,750 | 723,563 | 93,750 | |
| May 14 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 88.42 | 18,750 | 1,657,856 | 290,600 | 309.4 K to 290.6 K (-6.06 %) |
| May 14 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 38.59 | 18,750 | 723,563 | 309,350 | 290.6 K to 309.4 K (+6.45 %) |
| May 14 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 89.59 | 18,750 | 1,679,794 | 290,600 | 309.4 K to 290.6 K (-6.06 %) |
| May 14 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 38.59 | 18,750 | 723,563 | 309,350 | 290.6 K to 309.4 K (+6.45 %) |
| May 14 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Grant | A | 68.78 | 309 | 21,254 | 290,600 | 290.3 K to 290.6 K (+0.11 %) |
| May 14 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 38.59 | 18,750 | 723,563 | 75,000 | |
| May 14 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 38.59 | 18,750 | 723,563 | 93,750 | |
| May 14 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 88.42 | 18,750 | 1,657,856 | 290,600 | 309.4 K to 290.6 K (-6.06 %) |
| May 14 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 38.59 | 18,750 | 723,563 | 309,350 | 290.6 K to 309.4 K (+6.45 %) |
| May 14 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 89.59 | 18,750 | 1,679,794 | 290,600 | 309.4 K to 290.6 K (-6.06 %) |
| May 14 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 38.59 | 18,750 | 723,563 | 309,350 | 290.6 K to 309.4 K (+6.45 %) |
| May 14 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Grant | A | 68.78 | 309 | 21,254 | 290,600 | 290.3 K to 290.6 K (+0.11 %) |
| May 09 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 85.96 | 309 | 26,562 | 52,914 | 53.2 K to 52.9 K (-0.58 %) |
| May 09 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 68.78 | 309 | 21,254 | 53,223 | 52.9 K to 53.2 K (+0.58 %) |
| Apr 25 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 82.15 | 11,059 | 908,497 | 62,543 | 73.6 K to 62.5 K (-15.03 %) |
| Apr 25 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 38.59 | 10,000 | 385,900 | 112,500 | |
| Apr 25 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 38.59 | 10,000 | 385,900 | 122,500 | |
| Apr 25 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 82.29 | 10,000 | 822,887 | 290,031 | 300 K to 290 K (-3.33 %) |
| Apr 25 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 38.59 | 10,000 | 385,900 | 300,031 | 290 K to 300 K (+3.45 %) |
| Apr 25 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 82.58 | 10,000 | 825,811 | 290,031 | 300 K to 290 K (-3.33 %) |
| Apr 25 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 38.59 | 10,000 | 385,900 | 300,031 | 290 K to 300 K (+3.45 %) |
| Apr 25 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Sell | S | 82.15 | 11,059 | 908,497 | 62,543 | 73.6 K to 62.5 K (-15.03 %) |
| Apr 25 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 38.59 | 10,000 | 385,900 | 112,500 | |
| Apr 25 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 38.59 | 10,000 | 385,900 | 122,500 | |
| Apr 25 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 82.29 | 10,000 | 822,887 | 290,031 | 300 K to 290 K (-3.33 %) |
| Apr 25 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 38.59 | 10,000 | 385,900 | 300,031 | 290 K to 300 K (+3.45 %) |
| Apr 25 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 82.58 | 10,000 | 825,811 | 290,031 | 300 K to 290 K (-3.33 %) |
| Apr 25 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 38.59 | 10,000 | 385,900 | 300,031 | 290 K to 300 K (+3.45 %) |
| Apr 24 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 38.59 | 10,000 | 385,900 | 132,500 | |
| Apr 24 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 83.65 | 10,000 | 836,458 | 290,031 | 300 K to 290 K (-3.33 %) |
| Apr 24 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 38.59 | 10,000 | 385,900 | 300,031 | 290 K to 300 K (+3.45 %) |
| Apr 19 2018 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Option Exercise | M | 38.59 | 3,750 | 144,713 | 0 | |
| Apr 19 2018 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Sell | S | 85.00 | 3,750 | 318,750 | 14,860 | 18.6 K to 14.9 K (-20.15 %) |
| Apr 19 2018 | BMRN | BIOMARIN PHARMACEU ... | LAWLIS V BRYAN | Director | Buy | M | 38.59 | 3,750 | 144,713 | 18,610 | 14.9 K to 18.6 K (+25.24 %) |
| Apr 09 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 1,000 | 14,390 | 107,000 | |
| Apr 09 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 1,000 | 14,390 | 290,031 | 289 K to 290 K (+0.35 %) |
| Apr 03 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 80.12 | 2,119 | 169,774 | 52,914 | 55 K to 52.9 K (-3.85 %) |
| Apr 03 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 1,000 | 14,390 | 108,000 | |
| Apr 03 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 1,000 | 14,390 | 289,031 | 288 K to 289 K (+0.35 %) |
| Apr 03 2018 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Option Exercise | M | 37.46 | 6,650 | 249,109 | 20,681 | |
| Apr 03 2018 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Option Exercise | M | 26.49 | 3,350 | 88,742 | 1,875 | |
| Apr 03 2018 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Sell | S | 80.12 | 6,650 | 532,798 | 156,676 | 163.3 K to 156.7 K (-4.07 %) |
| Apr 03 2018 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Buy | M | 37.46 | 6,650 | 249,109 | 163,326 | 156.7 K to 163.3 K (+4.24 %) |
| Apr 03 2018 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Sell | S | 80.12 | 3,350 | 268,402 | 156,676 | 160 K to 156.7 K (-2.09 %) |
| Apr 03 2018 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Buy | M | 26.49 | 3,350 | 88,742 | 160,026 | 156.7 K to 160 K (+2.14 %) |
| Mar 30 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 79.69 | 1,537 | 122,484 | 55,033 | 56.6 K to 55 K (-2.72 %) |
| Mar 30 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 1,000 | 14,390 | 109,000 | |
| Mar 30 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 17.86 | 1,000 | 17,860 | 10,000 | |
| Mar 30 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 1,000 | 14,390 | 288,031 | 287 K to 288 K (+0.35 %) |
| Mar 30 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 17.86 | 1,000 | 17,860 | 287,031 | 286 K to 287 K (+0.35 %) |
| Mar 28 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 1,000 | 14,390 | 110,000 | |
| Mar 28 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 1,000 | 14,390 | 111,000 | |
| Mar 28 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 1,000 | 14,390 | 286,031 | 285 K to 286 K (+0.35 %) |
| Mar 28 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 1,000 | 14,390 | 285,031 | 284 K to 285 K (+0.35 %) |
| Mar 27 2018 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Sell | S | 81.35 | 3,350 | 272,523 | 87,989 | 91.3 K to 88 K (-3.67 %) |
| Mar 26 2018 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Payment of Exercise | F | 81.36 | 3,486 | 283,621 | 84,459 | 87.9 K to 84.5 K (-3.96 %) |
| Mar 26 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 81.36 | 3,583 | 291,513 | 56,570 | 60.2 K to 56.6 K (-5.96 %) |
| Mar 26 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 1,000 | 14,390 | 112,000 | |
| Mar 26 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Payment of Exercise | F | 81.36 | 13,075 | 1,063,782 | 284,031 | 297.1 K to 284 K (-4.40 %) |
| Mar 26 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 1,000 | 14,390 | 297,106 | 296.1 K to 297.1 K (+0.34 %) |
| Mar 26 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 81.36 | 3,583 | 291,513 | 73,602 | 77.2 K to 73.6 K (-4.64 %) |
| Mar 26 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Payment of Exercise | F | 81.36 | 414 | 33,683 | 17,559 | 18 K to 17.6 K (-2.30 %) |
| Mar 26 2018 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Payment of Exercise | F | 81.36 | 5,812 | 472,864 | 156,676 | 162.5 K to 156.7 K (-3.58 %) |
| Mar 26 2018 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Payment of Exercise | F | 81.36 | 3,295 | 268,081 | 91,339 | 94.6 K to 91.3 K (-3.48 %) |
| Mar 23 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 83.90 | 4,368 | 366,475 | 60,153 | 64.5 K to 60.2 K (-6.77 %) |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 38.59 | 15,000 | 578,850 | 142,500 | |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 83.26 | 15,000 | 1,248,854 | 296,106 | 311.1 K to 296.1 K (-4.82 %) |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 38.59 | 15,000 | 578,850 | 311,106 | 296.1 K to 311.1 K (+5.07 %) |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Sell | S | 83.88 | 3,818 | 320,254 | 94,634 | 98.5 K to 94.6 K (-3.88 %) |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Option Exercise | A | 83.57 | 9,120 | 762,158 | 9,120 | |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Grant | A | 0.00 | 5,710 | 0 | 17,973 | 12.3 K to 18 K (+46.56 %) |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Payment of Exercise | F | 84.10 | 346 | 29,099 | 12,263 | 12.6 K to 12.3 K (-2.74 %) |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Payment of Exercise | F | 83.57 | 309 | 25,823 | 12,609 | 12.9 K to 12.6 K (-2.39 %) |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | A | 83.57 | 148,190 | 12,384,238 | 148,190 | |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 38.59 | 15,000 | 578,850 | 157,500 | |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Grant | A | 0.00 | 46,340 | 0 | 296,106 | 249.8 K to 296.1 K (+18.55 %) |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Payment of Exercise | F | 83.57 | 14,908 | 1,245,862 | 249,766 | 264.7 K to 249.8 K (-5.63 %) |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 84.73 | 15,000 | 1,270,901 | 264,674 | 279.7 K to 264.7 K (-5.36 %) |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 38.59 | 15,000 | 578,850 | 279,674 | 264.7 K to 279.7 K (+5.67 %) |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Option Exercise | A | 83.57 | 38,760 | 3,239,173 | 38,760 | |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Grant | A | 0.00 | 12,120 | 0 | 98,452 | 86.3 K to 98.5 K (+14.04 %) |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Payment of Exercise | F | 83.57 | 3,757 | 313,972 | 86,332 | 90.1 K to 86.3 K (-4.17 %) |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Option Exercise | A | 83.57 | 51,300 | 4,287,141 | 51,300 | |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Grant | A | 0.00 | 16,040 | 0 | 162,488 | 146.4 K to 162.5 K (+10.95 %) |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Payment of Exercise | F | 83.57 | 4,861 | 406,234 | 146,448 | 151.3 K to 146.4 K (-3.21 %) |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Option Exercise | A | 83.57 | 38,760 | 3,239,173 | 38,760 | |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Grant | A | 0.00 | 12,120 | 0 | 87,945 | 75.8 K to 87.9 K (+15.98 %) |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Payment of Exercise | F | 83.57 | 3,644 | 304,529 | 75,825 | 79.5 K to 75.8 K (-4.59 %) |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Option Exercise | A | 83.57 | 41,040 | 3,429,713 | 41,040 | |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 0.00 | 12,840 | 0 | 64,521 | 51.7 K to 64.5 K (+24.84 %) |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 83.57 | 3,651 | 305,114 | 51,681 | 55.3 K to 51.7 K (-6.60 %) |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Option Exercise | A | 83.57 | 39,900 | 3,334,443 | 39,900 | |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 0.00 | 12,480 | 0 | 77,185 | 64.7 K to 77.2 K (+19.29 %) |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 83.57 | 3,815 | 318,820 | 64,705 | 68.5 K to 64.7 K (-5.57 %) |
| Mar 13 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 82.39 | 2,972 | 244,863 | 55,332 | 58.3 K to 55.3 K (-5.10 %) |
| Mar 07 2018 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Sell | S | 79.04 | 2,105 | 166,379 | 90,089 | 92.2 K to 90.1 K (-2.28 %) |
| Mar 06 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 1,000 | 14,390 | 113,000 | |
| Mar 06 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Payment of Exercise | F | 79.86 | 8,542 | 682,164 | 264,674 | 273.2 K to 264.7 K (-3.13 %) |
| Mar 06 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 1,000 | 14,390 | 273,216 | 272.2 K to 273.2 K (+0.37 %) |
| Mar 06 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 79.86 | 1,609 | 128,495 | 68,520 | 70.1 K to 68.5 K (-2.29 %) |
| Mar 06 2018 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Payment of Exercise | F | 79.86 | 2,576 | 205,719 | 151,309 | 153.9 K to 151.3 K (-1.67 %) |
| Mar 06 2018 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Payment of Exercise | F | 79.86 | 2,071 | 165,390 | 92,194 | 94.3 K to 92.2 K (-2.20 %) |
| Mar 06 2018 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Payment of Exercise | F | 79.86 | 1,615 | 128,974 | 79,469 | 81.1 K to 79.5 K (-1.99 %) |
| Mar 06 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 79.86 | 1,614 | 128,894 | 58,304 | 59.9 K to 58.3 K (-2.69 %) |
| Feb 28 2018 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Grant | A | 0.00 | 11,523 | 0 | 94,265 | 82.7 K to 94.3 K (+13.93 %) |
| Feb 28 2018 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Grant | A | 0.00 | 20,324 | 0 | 153,885 | 133.6 K to 153.9 K (+15.22 %) |
| Feb 28 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Grant | A | 0.00 | 45,722 | 0 | 272,216 | 226.5 K to 272.2 K (+20.19 %) |
| Feb 28 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 0.00 | 12,529 | 0 | 70,129 | 57.6 K to 70.1 K (+21.75 %) |
| Feb 28 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 0.00 | 12,529 | 0 | 59,918 | 47.4 K to 59.9 K (+26.44 %) |
| Feb 28 2018 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Grant | A | 0.00 | 12,190 | 0 | 81,084 | 68.9 K to 81.1 K (+17.69 %) |
| Feb 20 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 38.59 | 10,000 | 385,900 | 172,500 | |
| Feb 20 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 84.63 | 10,000 | 846,285 | 226,494 | 236.5 K to 226.5 K (-4.23 %) |
| Feb 20 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 38.59 | 10,000 | 385,900 | 236,494 | 226.5 K to 236.5 K (+4.42 %) |
| Feb 05 2018 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Option Exercise | M | 38.59 | 30,000 | 1,157,700 | 0 | |
| Feb 05 2018 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Sell | S | 90.66 | 30,000 | 2,719,665 | 82,942 | 112.9 K to 82.9 K (-26.56 %) |
| Feb 05 2018 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Buy | M | 38.59 | 30,000 | 1,157,700 | 112,942 | 82.9 K to 112.9 K (+36.17 %) |
| Jan 09 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 38.59 | 10,000 | 385,900 | 182,500 | |
| Jan 09 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 90.32 | 10,000 | 903,203 | 225,894 | 235.9 K to 225.9 K (-4.24 %) |
| Jan 09 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 38.59 | 10,000 | 385,900 | 235,894 | 225.9 K to 235.9 K (+4.43 %) |